SALT LAKE CITY, Nov. 5, 2013 /PRNewswire-iReach/ -- Dinesh Patel, PhD, co-founder of vSpring Capital (now Signal Peak Ventures), has joined the board of directors for Utah-based Tute Genomics, founded in 2012. Tute is a professional grade, cloud-based application for the rapid and cost-effective analysis of entire human genomes for healthcare & biomedical research. Tute Genomics comes at a time when the current pace of interpretation of genomic data cannot keep up with the increasing volume of big data that is flooding hospitals & research institutions, calling for a system to analyze these data fast enough to infer the biological insights needed to stay ahead and guide decision-making. This is the nature of Tute's business and is aligned well with Dr. Patel's knowledge base and skill set.
Dr. Patel brings with him decades of experience which, combined with his belief in the mission of Tute Genomics, are sure to provide a great advantage to the growing company. Dr. Patel has had leading roles at several life sciences companies. From 1985 to 1999, Dr. Patel served as Co-Founder, Chairman of the Board of Directors and President of TheraTech, Inc., a biotechnology company which he took public and eventually sold for $350 million to Watson Pharmaceuticals. From 1999 to 2004 he was the Founder, Chairman, and President of Ashni Naturaceuticals, Inc., a company that specializes in the research, development and marketing of clinically tested and patent-protected nutraceutical products. Prior to Signal Peak Ventures, Dr. Patel was an active angel investor in over 20 biotech and technology companies.
Dr. Patel also served on the board of Mediconnect Global, a worldwide leader in medical record retrieval, digitization, and one of the largest cloud-based health information exchanges. In March 2012, Mediconnect was acquired by Verisk Analytics (VRSK) for over $377 million.
Dr. Patel serves on several non-profit boards, and has won numerous awards including; 2010 Utah Youth Village Helping Hand Award, 2009 Utah Genius Lifetime Achievement Award, 2006 Utah Technology Council Hall of Fame Inductee, 2006 Ellis Island Medal of Honor, US Small Business Administration's Business Achiever Award, Scientific and Technology Award (State of Utah), Entrepreneur of the Year Award (Mountain West Venture Group) and Scientific and Technology Development Pioneer of Progress Award to name a few. He is also a charter member of The Indus Entrepreneurs (TiE).
Dr. Patel has also served as co-chair of Governor Huntsman's transition and he is the Chairman of the USTAR Governing Authority board. He is a member of the Life Sciences and Management Board at the University of Pennsylvania and on the National Advisory Board for theUniversity of Michigan's Technology Transfer Office.
Of his new role with Tute, Dr. Patel is excited to be a part of this promising company and states "Tute Genomics provides a unique and valuable solution to analyzing and understanding the human genome, and will play an important role in advancing personalized medicine."
About Tute Genomics:
Tute Genomics is a cloud-based clinical genome interpretation engine that is secure, robust, professional grade, and has the ability to analyze and annotate personal genomes in a rapid and cost-effective way. Whole genome sequencing is transforming research & medicine. Researchers and laboratories are getting flooded with high-throughput genetics data sets, but the ability to infer biological insights and guide decision making lag behind significantly. There is an urgent need for tools to analyze genetic variants from personal genomes in research and in clinical settings. Tute Genomics is solving this problem with a web-based clinical genome interpretation engine. To learn more about Tute Genomics, please go to www.tutegenomics.com
About Dinesh Patel:
Born and raised in Zambia, Africa, Dr. Patel received his bachelor's degree in Pharmacy at Gujarat University located in Ahmedabad, Gujarat, India. He earned his master's degree from the Philadelphia College of Pharmacy and his Ph.D. in Physical Pharmacy from the University of Michigan. Dr. Patel led the firm's investments in Altea Therapeutics, Axial, Exagen, Inflabloc, Protolex, Q Therapeutics, Zars and Salus Therapeutics which was acquired by Genta (NASDAQ: GNTA) for $30 million.
Media Contact:Lynn Dakoulas, Tute Genomics, 8017104035, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com